Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. To be honest, very good progress has been ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We already know CAR T, cellular therapy, ...

A blockbuster AstraZeneca drug may now be used as an earlier treatment for mantle cell lymphoma (MCL), making it the first in its class approved as a first-line therapy for this rare and aggressive ...

Authors Compare Bridging Therapy Strategies Prior to Brexu-Cel in MCL Meta-analysis across B-cell lymphomas shows zanubrutinib (Brukinsa) delivers higher ORR/CR than acalabrutinib (Calquence) or ...

Confirmatory ZUMA-2 trial data led to full FDA approval of brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.

Treatment with acalabrutinib/BR reduced the risk of disease progression or death by 27% compared with placebo/BR. The Food and Drug Administration (FDA) has granted Priority Review to acalabrutinib ...

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches. If you have the appropriate software installed, you can download article citation data to the citation manager ...

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said. Treatment with CAR-T cell therapy Breyanzi ...

Translocations are chromosomal “cut and paste” errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...

Mantle cell lymphoma (MCL) remains one of the more challenging B-cell non-Hodgkin lymphomas, distinguished by its aggressive clinical course and complex molecular signature. Recent investigations have ...